Bullish indicating open at $55-$60, IPO prices at $37
Gil M. Labrucherie, the Chief Financial Officer of Septerna, Inc. (NASDAQ:SEPN), has recently acquired a significant amount of the company’s common stock, according to a recent SEC filing. Over a series of transactions, Labrucherie purchased a total of 30,000 shares, valued at approximately $172,296. The insider purchase comes as the stock has declined over 70% in the past year, with InvestingPro data showing analyst price targets ranging from $14 to $38.
The acquisitions occurred on three consecutive days. On February 19, Labrucherie bought 10,500 shares at a weighted average price of $5.506 per share. The following day, he acquired an additional 14,500 shares, with the price ranging from $5.58 to $6.12, resulting in a weighted average price of $5.8782. The final purchase of 5,000 shares was made on February 21, at a price range of $5.77 to $5.88. InvestingPro analysis indicates the stock is currently in oversold territory, with the company maintaining a strong liquidity position and a current ratio of 10.08.
These shares are held directly by The Labrucherie Trust, for which Labrucherie serves as trustee. The transactions reflect Labrucherie’s continued confidence in Septerna, a pharmaceutical company based in South San Francisco, California. With the company’s next earnings report due on February 26, InvestingPro subscribers can access 12 additional key insights about Septerna’s financial health and market position.
In other recent news, Septerna, Inc. announced the discontinuation of its Phase 1 clinical trial for SEP-786, a treatment aimed at hypoparathyroidism, due to elevated bilirubin levels in participants. Despite the trial halt, the company remains committed to its development goals, with plans to select a next-generation candidate from its PTH1R agonists for future trials. JPMorgan maintained its Overweight rating on Septerna, with a $38 price target, despite the trial setback, indicating confidence in the company’s broader pipeline and strategy. Cantor Fitzgerald also reaffirmed its Overweight rating with a $50 price target, highlighting the potential for significant growth in the hypoPTH treatment market.
Septerna reported $137.5 million in cash and securities as of September 2024, with additional funds from its IPO expected to support operations into the second half of 2027. The company is also advancing SEP-631, targeting mast cell diseases, with clinical trials expected to commence soon. In a strategic move, Septerna appointed Gil Labrucherie as its new Chief Financial Officer, bringing extensive finance and legal experience to bolster its financial strategy. These developments underscore Septerna’s ongoing efforts to navigate challenges and capitalize on opportunities within the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.